Literature DB >> 23076705

Unexpected remission of hepatocellular carcinoma (HCC) with lung metastasis to the combination therapy of thalidomide and cyproheptadine: report of two cases and a preliminary HCC cell line study.

Yu-Min Feng1, Chin-Wen Feng, Solomon Chih-Cheng Chen, Cheng-Da Hsu.   

Abstract

We reported two cases of hepatocellular carcinoma (HCC) with lung metastases who were treated with a combination of thalidomide and cyproheptadine. The use of cyproheptadine in these two cases was originally for skin itching. Follow-up CT images revealed a complete remission of HCC in both of them after treatment for 6 months and 6 weeks, respectively. A following experimental cell line study demonstrated that cyproheptadine effectively reduced the viability of two HCC cell lines.

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 23076705      PMCID： PMC4543862          DOI： 10.1136/bcr-2012-007180

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN： 1757-790X


  15 in total

1.  Management of hepatocellular carcinoma.

Authors:  Jordi Bruix; Morris Sherman
Journal:  Hepatology       Date:  2005-11       Impact factor: 17.425

2.  Cyproheptadine: a potent in vivo serotonin antagonist.

Authors:  S Kapur; R B Zipursky; C Jones; A A Wilson; J D DaSilva; S Houle
Journal:  Am J Psychiatry       Date:  1997-06       Impact factor: 18.112

3.  A controlled trial of cyproheptadine in cancer patients with anorexia and/or cachexia.

Authors:  C G Kardinal; C L Loprinzi; D J Schaid; A C Hass; A M Dose; L M Athmann; J A Mailliard; G W McCormack; J B Gerstner; M F Schray
Journal:  Cancer       Date:  1990-06-15       Impact factor: 6.860

4.  Chlorpheniramine inhibits the synthesis of ornithine decarboxylase and the proliferation of human breast cancer cell lines.

Authors:  M A Medina; R García de Veas; P Morata; J Lozano; F Sánchez-Jiménez
Journal:  Breast Cancer Res Treat       Date:  1995-08       Impact factor: 4.872

5.  The anti-histaminic cyproheptadine synergizes the antineoplastic activity of bortezomib in mantle cell lymphoma through its effects as a histone deacetylase inhibitor.

Authors:  Luca Paoluzzi; Luigi Scotto; Enrica Marchi; Venkatraman E Seshan; Owen A O'Connor
Journal:  Br J Haematol       Date:  2009-07-08       Impact factor: 6.998

6.  Loratadine dysregulates cell cycle progression and enhances the effect of radiation in human tumor cell lines.

Authors:  Benjamin P Soule; Nicole L Simone; William G DeGraff; Rajani Choudhuri; John A Cook; James B Mitchell
Journal:  Radiat Oncol       Date:  2010-02-03       Impact factor: 3.481

7.  Selective COX-2 inhibitor, NS-398, suppresses cellular proliferation in human hepatocellular carcinoma cell lines via cell cycle arrest.

Authors:  Ji Yeon Baek; Wonhee Hur; Jin Sang Wang; Si Hyun Bae; Seung Kew Yoon
Journal:  World J Gastroenterol       Date:  2007-02-28       Impact factor: 5.742

8.  Serotonin promotes tumor growth in human hepatocellular cancer.

Authors:  Christopher Soll; Jae Hwi Jang; Marc-Oliver Riener; Wolfgang Moritz; Peter Johannes Wild; Rolf Graf; Pierre-Alain Clavien
Journal:  Hepatology       Date:  2010-04       Impact factor: 17.425

9.  Cyproheptadine displays preclinical activity in myeloma and leukemia.

Authors:  Xinliang Mao; Sheng-ben Liang; Rose Hurren; Marcela Gronda; Sue Chow; G Wei Xu; Xiaoming Wang; Reza Beheshti Zavareh; Nazir Jamal; Hans Messner; David W Hedley; Alessandro Datti; Jeff L Wrana; Yuanxiao Zhu; Chang-xin Shi; Kyle Lee; Rodger Tiedemann; Suzanne Trudel; A Keith Stewart; Aaron D Schimmer
Journal:  Blood       Date:  2008-05-23       Impact factor: 22.113

10.  Sorafenib in advanced hepatocellular carcinoma.

Authors:  Josep M Llovet; Sergio Ricci; Vincenzo Mazzaferro; Philip Hilgard; Edward Gane; Jean-Frédéric Blanc; Andre Cosme de Oliveira; Armando Santoro; Jean-Luc Raoul; Alejandro Forner; Myron Schwartz; Camillo Porta; Stefan Zeuzem; Luigi Bolondi; Tim F Greten; Peter R Galle; Jean-François Seitz; Ivan Borbath; Dieter Häussinger; Tom Giannaris; Minghua Shan; Marius Moscovici; Dimitris Voliotis; Jordi Bruix
Journal:  N Engl J Med       Date:  2008-07-24       Impact factor: 91.245
View more
  10 in total

1.  Cyproheptadine use in hepatocellular carcinoma.

Authors:  Mao-Chih Hsieh; Wei-Hua Lee; Alexander Th Wu; Jyh-Ming Chow; Chia-Lun Chang; Kevin Sheng-Po Yuan; Szu-Yuan Wu
Journal:  Am J Cancer Res       Date:  2017-03-01       Impact factor: 6.166

2.  Emodin-Loaded PLGA-TPGS Nanoparticles Combined with Heparin Sodium-Loaded PLGA-TPGS Nanoparticles to Enhance Chemotherapeutic Efficacy Against Liver Cancer.

Authors:  Hongyan Liu; Hong Xu; Chenghong Zhang; Meng Gao; Xiaoguang Gao; Chuchu Ma; Li Lv; Dongyan Gao; Sa Deng; Changyuan Wang; Yan Tian
Journal:  Pharm Res       Date:  2016-08-10       Impact factor: 4.200

3.  Cyproheptadine, an antihistaminic drug, inhibits proliferation of hepatocellular carcinoma cells by blocking cell cycle progression through the activation of P38 MAP kinase.

Authors:  Yu-Min Feng; Chin-Wen Feng; Syue-Yi Chen; Hsiao-Yen Hsieh; Yu-Hsin Chen; Cheng-Da Hsu
Journal:  BMC Cancer       Date:  2015-03-17       Impact factor: 4.430

Review 4.  Chemotherapeutic agents for the treatment of hepatocellular carcinoma: efficacy and mode of action.

Authors:  Saad Shaaban; Amr Negm; Elsayed E Ibrahim; Ahmed A Elrazak
Journal:  Oncol Rev       Date:  2014-05-28

5.  Successful resection of hepatocellular cancer not amenable to Milan criteria and durable complete remission induced by systemic polichemotherapy after development of metastases - should we think about revising the current treatment guidelines in selected patients?

Authors:  Ivana Rados; Sasa Badzek; Hilda Golem; Juraj Prejac; Irma Gorsic; Domina Kekez; Niksa Librenjak; Stjepko Plestina
Journal:  World J Surg Oncol       Date:  2013-09-22       Impact factor: 2.754

6.  Cyproheptadine significantly improves the overall and progression-free survival of sorafenib-treated advanced HCC patients.

Authors:  Yu-Min Feng; Chin-Wen Feng; Chin-Li Lu; Ming-Yang Lee; Chi-Yi Chen; Solomon Chih-Cheng Chen
Journal:  Jpn J Clin Oncol       Date:  2015-02-02       Impact factor: 3.019

7.  Significant symptoms alleviation and tumor volume reduction after combined simultaneously integrated inner-escalated boost and volumetric-modulated arc radiotherapy in a patient with unresectable bulky hepatocellular carcinoma: A care-compliant case report.

Authors:  Young-Hsiang Lin; Shih-Kai Hung; Wen-Yen Chiou; Moon-Sing Lee; Bing-Jie Shen; Liang-Cheng Chen; Dai-Wei Liu; Wei-Ta Tsai; Po-Hao Lin; Yi-Ting Shih; Feng-Chun Hsu; Shiang-Jiun Tsai; Michael W Y Chan; Hon-Yi Lin
Journal:  Medicine (Baltimore)       Date:  2016-08       Impact factor: 1.889

8.  Efficacy of Cyproheptadine Monotherapy in Hepatocellular Carcinoma With Bone Metastasis: A Case Report.

Authors:  Yu-Min Feng; Tsung-Hsien Chen; Dara Berman; Chu-Kuang Chou; Kai-Sheng Liao; Ming-Chih Hsieh; Chi-Yi Chen
Journal:  Front Oncol       Date:  2021-10-20       Impact factor: 6.244

Review 9.  OPALS: A New Osimertinib Adjunctive Treatment of Lung Adenocarcinoma or Glioblastoma Using Five Repurposed Drugs.

Authors:  Richard E Kast; Marc-Eric Halatsch; Rafael Rosell
Journal:  Cells       Date:  2021-05-10       Impact factor: 6.600

10.  H1-Antihistamines Reduce the Risk of Hepatocellular Carcinoma in Patients With Hepatitis B Virus, Hepatitis C Virus, or Dual Hepatitis B Virus-Hepatitis C Virus Infection.

Authors:  Yu-Chuan Shen; Hui-Ching Hsu; Tzu-Min Lin; Yu-Sheng Chang; Li-Fang Hu; Lung-Fang Chen; Sheng-Hong Lin; Pei-I Kuo; Wei-Sheng Chen; Yi-Chun Lin; Jin-Hua Chen; Yu-Chih Liang; Chi-Ching Chang
Journal:  J Clin Oncol       Date:  2022-01-19       Impact factor: 50.717
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.